Trial Profile

Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sargramostim (Primary) ; Cyclophosphamide; Granulocyte colony-stimulating factors
Indications Engraftment; Haematological malignancies
Focus Therapeutic Use

17 Oct 2024 Planned primary completion date changed from 18 Sep 2024 to 18 Sep 2025.
12 Apr 2024 Planned End Date changed from 18 May 2025 to 18 Sep 2025.
12 Apr 2024 Planned primary completion date changed from 18 May 2024 to 18 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com